Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Nordic Nanovector ASA ( (DE:8NN) ) has provided an update.
Thor Medical ASA has secured a NOK 90 million loan facility from Innovation Norway, fully financing its first commercial-scale plant, AlphaOne, which is expected to significantly enhance the company’s production capabilities. With the plant projected to generate NOK 400 million in revenue at full capacity, Thor Medical’s expansion is poised to support major advancements in cancer treatment, thereby solidifying its position in the healthcare industry and supporting Norway’s export initiatives.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier of radionuclides, primarily focusing on alpha particle emitters derived from naturally occurring thorium. The company employs a proprietary production process that does not require irradiation or nuclear reactors, offering a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Headquartered in Oslo, Norway, Thor Medical is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
YTD Price Performance: 2.74%
Average Trading Volume: 5,336
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €64.24M
See more insights into 8NN stock on TipRanks’ Stock Analysis page.
